Clinical Trial Search

Primary: Erectile Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain — 14; 19 score on a scale

Primary: Maximum Observed Plasma Concentration (Cmax) — 0.281; 2.29; 2.74 (ng/mL)/(mg)

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 14; 7; 1 Participants

Primary: Percentage of Participants With Severe Diarrhea (≥ Grade 3) — 4.2; 0; 0 percentage of participants

Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)…

Primary: Number of Participants With Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants

Primary: Changes From Baseline in Lipid Profile at 8 Weeks — 52; 56.1; 184.3; 181.7 mg/dL

Primary: Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks) — 6; 4 Participants

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events — 5; 5; 3; 4 Participants

Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion

Primary: Change From Baseline in Interferon-Gamma Spot Forming Units (IFN-gamma SFUs) in a Gliadin-specific Enzyme-linked Immunospot (ELISpot) at Day 20 — 3.08; 1.98; 2.01; 17.57…

Primary: Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) — 8.3; 0.0; 0.0…

Primary: Percentage of Participants Alive Without Progression at Two Years (Progression-free Survival) — 90.5; 87.6 percentage of participants — p=0.04

Primary: Testosterone Levels — 1.02; 1.05 ng/dL — p=0.4879